1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Guobang Pharma Ltd.

Guobang Pharma Ltd.

605507.SS
Guobang Pharma Ltd.CN flagShanghai Stock Exchange
15.93
CNY
+0.17
- -
12.46BMarket Cap
Guobang Pharma Ltd.
605507.SS
(Shanghai Stock Exchange)

Recent

price

15.93

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
5.69
6.34
6.29
7.32
6.86
7.54
7.74
5.99
Revenue per Share
- -
- -
0.47
1.22
0.99
1.18
0.79
1
1.06
0.71
Basic EPS, GAAP
- -
- -
-0.25
0.37
-0.87
0.27
-0.3
0.37
0.36
-0.28
Free Cash Flow per Basic Share
- -
- -
0.05
0.28
0.47
0.16
0.46
0.25
0.46
0.46
Dividend per Share
- -
- -
2.32
3.32
3.65
4.36
4.67
5.41
6.03
6.25
Book Value per Share
- -
- -
3.5
4.53
8.48
8.68
9.08
9.85
10.58
10.8
Tangible Book Value per Share
- -
- -
668
663
716
781
779
782
776
775
Basic Weighted Avg Shares
2,905
3,279
3,802
4,206
4,505
5,721
5,349
5,891
6,011
4,649
Sales/Revenue/Turnover
18.15
18.94
15.56
24.49
19.5
17.5
12.32
15.02
16
15.1
Operating Margin (%)
116
132
138
157
201
260
321
433
478
- -
Depreciation Expense
178
211
315
810
706
921
612
782
821
552
Net Income, GAAP
13.61
13.95
14.22
14.11
12.46
11.11
12.57
12.09
14.05
13.6
Effective Tax Rate (%)
6.12
6.43
8.28
19.26
15.67
16.1
11.45
13.27
13.65
11.87
Profit Margin (%)
613
1,118
1,187
898
3,414
3,267
2,994
3,317
4,192
3,961
Working Capital
- -
27
483
251
- -
- -
452
147
478
83
LT Debt
2,207
2,593
2,616
3,274
6,346
7,155
7,437
8,052
8,556
8,716
Total Equity
- -
17.07
14.92
22.89
14.35
12.43
7.12
9.03
8.99
6.35
Return on Invested Capital (%)
- -
-1.11
5.91
30.21
24.83
27.39
14.64
16.78
15.81
10.11
Return on Capital (%)
- -
19.25
23.09
43.16
29.31
30.6
17.38
19.87
18.42
11.88
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
513
911
LT Borrowings
- -
478
83
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
782
782
782
Market Capitalization
12,910
14,027
14,392

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
6,113
6,532
Cash, Cash Equivalents & STI
- -
2,703
2,765
Accounts Receivable, Net
- -
859
1,017
Inventories
- -
1,776
1,741
Total Current Liabilities
- -
1,921
2,571
Payables & Accruals
- -
- -
- -
ST Debt
- -
513
911
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
25.01%
6.25%
Free Cash Flow
- -
-184.15%
-1.99%
Net Income, GAAP
- -
3.35%
5.02%
Sales/Revenue/Turnover
- -
7.95%
2.05%
Total Cash Common Dividend
- -
47.38%
85.28%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,339
1,554
1,526
1,473
5,891
2025
1,440
1,586
- -
1,542
6,011
2026
1,521
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.26
- -
- -
- -
1
2025
0.27
- -
- -
- -
1.06
2026
0.21
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
- -
- -
0.25
2025
0.01
- -
- -
- -
0.46
2026
0.01
- -
- -
- -
- -
Similar Companies
Greenrose Acquisition Corp. (GNRSW)
Medcolcanna Organics Inc. (MCCN.CN)
Kaken Pharmaceutical Co., Ltd. (KKPCF)
Yuyu Pharma, Inc. (000220.KS)
Ecofibre Limited (EOF.AX)
Western Sierra Resource Corporation (WSRC)
Business
Guobang Pharma Ltd. (605507.SS) engages in the research, development, production and sale of active pharmaceutical ingredients (APIs), key intermediates and formulations for human pharmaceuticals and veterinary products. The company manufactures macrolides including azithromycin, clarithromycin and roxithromycin; quinolones such as ciprofloxacin hydrochloride, ciprofloxacin lactate, ciprofloxacin mesylate, moxifloxacin and enrofloxacin; special APIs like azelnidipine, budesonide, mitiglinide, doxifluridine, solifenacin and vildagliptin; veterinary APIs including marbofloxacin and diclazuril; cephalosporins; characteristic APIs; kinetochore preparations; feed additives; and key intermediates such as dihydrohomoerythromycin, erythromycin oxime and cyclopropanecarboxylic acid. Founded in 1996 and headquartered at No. 60 Xingmei Avenue, Meizhu Town, Xinchang County, Shaoxing, China, Guobang Pharma operates a global sales network serving approximately 110 to 112 countries and regions with significant market share exceeding 35% in key products for both Chinese and international markets; it employs around 4,000 people and maintains facilities including a national postdoctoral workstation, provincial research institute and enterprise technology center with certifications from FDA, EU GMP, PMDA, ANVISA and MFDS. Recent developments include authorization of a CNY 200 million share buyback plan in March 2025 with ongoing repurchases totaling over 5 million shares by late 2025; an agreement in August 2025 for Zhejiang State-owned Capital Operation Co., Ltd. to acquire a 6.85% stake for approximately CNY 790 million; German GMP certification in June 2025 for a swine and cattle respiratory drug; subsidiary approval in February 2025 for domestic production of cefuroxime axetil API; and a unit's florfenicol production passing US FDA inspection in December 2024.